

To: [REDACTED] 5.1.2e [REDACTED] 5.1.2e @rivm.nl]
 From: [REDACTED] 5.1.2e /FR
 Sent: Wed 3/9/2022 9:27:09 AM
 Subject: RE: Inno4Vac Steering Committee Recurring Meeting
 Received: Wed 3/9/2022 9:27:17 AM

Thanks for the deck preparation and sharing.
 See you later today.

Best

[REDACTED] 5.1.2e

De : [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @rivm.nl>
 Envoyé : mercredi 9 mars 2022 10:01
 À : [REDACTED] 5.1.2e /FR <[REDACTED] 5.1.2e @sanofi.com>; [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @euvaccine.eu>;
 [REDACTED] 5.1.2e @euvaccine.eu
 Cc : [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @euvaccine.eu>; [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @euvaccine.eu>
 Objet : RE: Inno4Vac Steering Committee Recurring Meeting

Hi [REDACTED] 5.1.2e
 Thank you for letting us know. I uploaded the ST3 update for today in the SC TC11 sharepoint folder...(also attached).
 Best, [REDACTED] 5.1.2e

[REDACTED] 5.1.2e^{1,2}
¹Centre for Immunology of Infectious Diseases and Vaccines | National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 | PO box 1 | 3720 BA BILTHOVEN | The Netherlands
²Infectious Diseases & Immunology | Dept. Biomolecular Health Sciences | Faculty of Veterinary Medicine | Utrecht University | Yalelaan 1 | PO box 80165 | 3508 TD UTRECHT | The Netherlands
 T: [REDACTED] 5.1.2e | E: [REDACTED] 5.1.2e @rivm.nl

Van: [REDACTED] 5.1.2e /FR <[REDACTED] 5.1.2e @sanofi.com>
 Verzonden: woensdag 9 maart 2022 09:55
 Aan: Daniel Reem <[REDACTED] 5.1.2e @euvaccine.eu>; [REDACTED] 5.1.2e @euvaccine.eu
 CC: [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @rivm.nl>; [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @euvaccine.eu>
 Onderwerp: RE: Inno4Vac Steering Committee Recurring Meeting

Dear [REDACTED] 5.1.2e

Due to an agenda conflict, I won't be able to join the first hour of the SC meeting today.
 So sorry for this.

I will join at 2pm.
 Thanks

[REDACTED] 5.1.2e

-----Rendez-vous d'origine-----
 De : [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @euvaccine.eu>
 Envoyé : vendredi 3 décembre 2021 13:48

À : [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] 5.1.2e
 [REDACTED] 5.1.2e @sclavo.org; [REDACTED] 5.1.2e (PARA); [REDACTED] 5.1.2e ; [REDACTED] 5.1.2e ;
 Cc : [REDACTED] 5.1.2e [REDACTED] 5.1.2e (PARA); [REDACTED] 5.1.2e ; [REDACTED] 5.1.2e ; [REDACTED] 5.1.2e ; [REDACTED] 5.1.2e ;
 [REDACTED] 5.1.2e

Objet : Inno4Vac Steering Committee Recurring Meeting
 Date : mercredi 9 mars 2022 13:00-15:00 (UTC+01:00) Amsterdam, Berlin, Berne, Rome, Stockholm, Vienne.

Où : GoTo Meeting

Please join my meeting from your computer, tablet or smartphone.

5.1.2i Digitale overleggen

You can also dial in using your phone.

United States: 5.1.2i Digitale overleggen

Access Code: 5.1.2i Digitale overleggen

More phone numbers:

Australia: 5.1.2i Digitale overleggen

Austria: 5.1.2i Digitale overleggen

Belgium: 5.1.2i Digitale overleggen

Canada: 5.1.2i Digitale overleggen

Denmark: 5.1.2i Digitale overleggen

Finland: 5.1.2i Digitale overleggen

France: 5.1.2i Digitale overleggen

Germany: 5.1.2i Digitale overleggen

Ireland: 5.1.2i Digitale overleggen

Italy: 5.1.2i Digitale overleggen

Netherlands: 5.1.2i Digitale overleggen

New Zealand: 5.1.2i Digitale overleggen

Norway: 5.1.2i Digitale overleggen

Spain: 5.1.2i Digitale overleggen

Sweden: 5.1.2i Digitale overleggen

Switzerland: 5.1.2i Digitale overleggen

United Kingdom: 5.1.2i Digitale overleggen

Join from a video-conferencing room or system.

Dial in or type: 5.1.2i Digitale overleggen or 5.1.2i Digitale overleggen

Meeting ID: 5.1.2i Digitale overleggen

Or dial directly: 5.1.2i Digitale overleggen or 5.1.2i Digitale overleggen

New to GoToMeeting? Get the app now and be ready when your first meeting

starts: 5.1.2i Digitale overleggen

 Cette communication (y compris les pieces jointes) est reservee a l'usage exclusif du destinataire (des destinataires) et peut contenir des informations privilegiees, confidentielles, exemptees de divulgation selon la loi ou protegees par les droits d'auteur. Si vous n'etes pas un destinataire, toute utilisation, divulgation, distribution, reproduction, examen ou copie (totale ou partielle) est non-autorisee et peut etre illegale. Tout message electronique est susceptible d'alteration et son integrite ne peut etre assuree. Sanofi Pasteur decline toute responsabilite au titre de ce message s'il a ete modifie ou falsifie. Si vous n'etes pas destinataire de ce message, merci de le detruire immediatement et d'avertir l'expediteur de l'erreur de distribution et de la destruction du message. Merci.

This transmission (including any attachments) is intended solely for the use of the addressee(s) and may contain confidential information including trade secrets which are privileged, confidential, exempt from disclosure under applicable law and/or subject to copyright. If you are not an intended recipient, any use, disclosure, distribution, reproduction, review or copying (either whole or partial) is unauthorized and may be unlawful. E-mails are susceptible to alteration and their integrity cannot be guaranteed. Sanofi Pasteur shall not be liable for this e-mail if modified or falsified. If you are not the intended recipient of this e-mail, please delete it immediately from your system and notify the sender of the wrong delivery and the mail deletion. Thank you.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to health and sustainability

Cette communication (y compris les pieces jointes) est reservee a l'usage exclusif du destinataire (des destinataires) et peut contenir des informations privilegiees, confidentielles, exemptees de divulgation selon la loi ou protegees par les droits d'auteur. Si vous n'etes pas un destinataire, toute utilisation, divulgation, distribution, reproduction, examen ou copie (totale ou partielle) est non-autorisee et peut etre illegale. Tout message electronique est susceptible d'alteration et son integrite ne peut etre assuree. Sanofi Pasteur decline toute responsabilite au titre de ce message s'il a ete modifie ou falsifie. Si vous n'etes pas destinataire de ce message, merci de le detruire immediatement et d'avertir l'expediteur de l'erreur de distribution et de la destruction du message. Merci.

This transmission (including any attachments) is intended solely for the use of the addressee(s) and may contain confidential information including trade secrets which are privileged, confidential, exempt from disclosure under applicable law and/or subject to copyright. If you are not an intended recipient, any use, disclosure, distribution, reproduction, review or copying (either whole or partial) is unauthorized and may be unlawful. E-mails are susceptible to alteration and their integrity cannot be guaranteed. Sanofi Pasteur shall not be liable for this e-mail if modified or falsified. If you are not the intended recipient of this e-mail, please delete it immediately from your system and notify the

sender of the wrong delivery and the mail deletion. Thank you.
